Cargando…
Statins in cardiometabolic disease: what makes pitavastatin different?
The term cardiometabolic disease encompasses a range of lifestyle-related conditions, including Metabolic syndrome (MetS) and type 2 diabetes (T2D), that are characterized by different combinations of cardiovascular (CV) risk factors, including dyslipidemia, abdominal obesity, hypertension, hypergly...
Autor principal: | Ginsberg, Henry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668186/ https://www.ncbi.nlm.nih.gov/pubmed/23819727 http://dx.doi.org/10.1186/1475-2840-12-S1-S1 |
Ejemplares similares
-
Pitavastatin in cardiometabolic disease: therapeutic profile
por: Masana, Luis
Publicado: (2013) -
Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin
por: Tokgözoglu, Lale, et al.
Publicado: (2020) -
Statin diabetogenicity: guidance for clinicians
por: Ray, Kausik
Publicado: (2013) -
Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus
por: Kawai, Yasuyuki, et al.
Publicado: (2011) -
Mini-Review on the Efficacy and Safety of Pitavastatin: “The Novel Seventh Statin Gaining Momentum”
por: Ramadan, Azza, et al.
Publicado: (2022)